Apixaban Dosing for DVT Treatment
For acute DVT treatment, start apixaban at 10 mg orally twice daily for the first 7 days, then reduce to 5 mg orally twice daily for continued treatment. 1
Initial Treatment Phase (First 7 Days)
- Dose: 10 mg orally twice daily
- Duration: Exactly 7 days
- No parenteral lead-in required: Unlike dabigatran or edoxaban, apixaban does not require initial heparin or LMWH 2
- This high-dose initiation phase is critical and should not be abbreviated
Maintenance Treatment Phase (After Day 7)
- Dose: 5 mg orally twice daily
- Duration: Minimum 3-6 months for most patients 2, 1
- Continue this dose through the completion of initial treatment period
Extended/Secondary Prevention (After 6+ Months)
If extended anticoagulation is indicated after completing initial treatment:
- Reduced-dose option: 2.5 mg orally twice daily 2, 3, 1
- Standard-dose option: Continue 5 mg orally twice daily 3, 4
The reduced dose (2.5 mg twice daily) is preferred for extended therapy as it provides effective VTE prevention with significantly less bleeding risk compared to full-dose therapy 3, 5. This is particularly important in cancer patients, where reduced-dose apixaban showed non-inferiority for preventing recurrent VTE with 25% lower clinically relevant bleeding 5.
Dose Adjustments
Reduce dose by 50% if patient is on combined P-glycoprotein AND strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir):
- 10 mg twice daily becomes 5 mg twice daily
- 5 mg twice daily becomes 2.5 mg twice daily
- Avoid apixaban entirely if patient already on 2.5 mg twice daily 1
Special Populations
Cancer-associated DVT: While LMWH remains preferred for initial treatment 6, 7, 8, apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily is an acceptable alternative for patients without high gastrointestinal or genitourinary bleeding risk 8. Recent evidence shows reduced-dose apixaban (2.5 mg twice daily) for extended treatment in cancer patients is non-inferior to full-dose with less bleeding 5.
Renal impairment: No dose adjustment needed for creatinine clearance ≥30 mL/min. Apixaban is contraindicated if CrCl <15 mL/min 9.
Common Pitfalls to Avoid
Do NOT subtract parenteral anticoagulation days from the 7-day lead-in period - If a patient received heparin/LMWH before apixaban, still give the full 10 mg twice daily for 7 days 10, 11
Do NOT use atrial fibrillation dosing (5 mg twice daily) for acute DVT - The 10 mg twice daily initiation is essential 2
Do NOT use reduced-dose (2.5 mg twice daily) during initial treatment - This dose is only for extended prevention after completing ≥6 months of treatment 3, 1
Timing matters: Can be taken with or without food, but maintain consistent 12-hour intervals between doses 1
Switching from Other Anticoagulants
- From warfarin: Start apixaban when INR <2.0 1
- From LMWH/heparin: Start apixaban at the time of next scheduled parenteral dose 1
The evidence strongly supports this dosing regimen, with the AMPLIFY trial demonstrating non-inferiority to enoxaparin/warfarin with significantly less major bleeding (0.6% vs 1.8%) 1.